INITIO Medical Group

INITIO Medical Group is a private Canadian healthcare company focused on nuclear medicine, PET/CT imaging, theranostics, and related clinical research services. Based in Burnaby, British Columbia, the company operates Western Canada’s only private PET/CT and private nuclear medicine facility and provides rapid-access diagnostic scans and targeted radiotherapy with a commercial service model. Its oncology offerings include gallium-68 PSMA-PET imaging and lutetium-177 PSMA therapy for prostate cancer, as well as gallium-68 imaging for neuroendocrine cancer. INITIO also supports clinical trials with PET/CT scanning and targeted radiotherapy services across oncology and neurodegenerative disease. The company has positioned itself as a precision oncology and theranostics provider rather than a drug developer, and in 2025 it was recognized by the ICPO Foundation as the first Theranostics Clinical Center of Excellence in Canada and North America.